Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical trial data translates to real-world practice. In addition to immune checkpoint inhibitor therapies, other emerging therapies for endometrial cancer (EC) are generating promising data, including novel immunotherapies, HER2 inhibitors, and bispecific antibodies. Members of the multidisciplinary care team who care for patients with EC need to know about emerging therapies that are poised to change practice patterns.
In the second activity of this CME Outfitters podcast series on gynecologic cancers, Drs. Richard Penson and Matthew Powell will present and discuss the very latest research on emerging treatment options for EC.
At the conclusion of this activity, learners will be able to better:
Supported by independent educational grants from AstraZeneca Pharmaceuticals and Merck & Co., Inc., Rahway, NJ, USA
Gynecologic oncologists, medical oncologists, gynecologists, physician associates (PAs), nurses, nurse practitioners (NPs), and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy credit (JA0007185-0000-24-091-H01-P).
This activity is designated for 0.75 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 09/30/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Penson reports the following financial relationships:
Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics
Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche
Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD, and CME Outfitters
Dr. Powell reports the following financial relationships:
Consultant: AstraZeneca; Eisai Inc.; Genmab; GSK; and Merck & Co., Inc.
Research Support: GSK
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
PD-109-093024-90
